IL123079A0 - Compositions and methods for producing a cancer growth inhibiting response - Google Patents

Compositions and methods for producing a cancer growth inhibiting response

Info

Publication number
IL123079A0
IL123079A0 IL12307996A IL12307996A IL123079A0 IL 123079 A0 IL123079 A0 IL 123079A0 IL 12307996 A IL12307996 A IL 12307996A IL 12307996 A IL12307996 A IL 12307996A IL 123079 A0 IL123079 A0 IL 123079A0
Authority
IL
Israel
Prior art keywords
compositions
producing
methods
cancer growth
growth inhibiting
Prior art date
Application number
IL12307996A
Other languages
English (en)
Original Assignee
Pacific Northwest Cancer Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacific Northwest Cancer Found filed Critical Pacific Northwest Cancer Found
Publication of IL123079A0 publication Critical patent/IL123079A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/58—Prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IL12307996A 1995-07-31 1996-07-29 Compositions and methods for producing a cancer growth inhibiting response IL123079A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/509,254 US5788963A (en) 1995-07-31 1995-07-31 Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
PCT/US1996/012389 WO1997004802A1 (en) 1995-07-31 1996-07-29 Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy

Publications (1)

Publication Number Publication Date
IL123079A0 true IL123079A0 (en) 1998-09-24

Family

ID=24025874

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12307996A IL123079A0 (en) 1995-07-31 1996-07-29 Compositions and methods for producing a cancer growth inhibiting response

Country Status (9)

Country Link
US (2) US5788963A (https=)
EP (2) EP2377548A3 (https=)
JP (1) JP4267692B2 (https=)
AU (1) AU723607B2 (https=)
CA (1) CA2228176C (https=)
DE (1) DE841940T1 (https=)
IL (1) IL123079A0 (https=)
NZ (1) NZ315441A (https=)
WO (1) WO1997004802A1 (https=)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US20020168374A1 (en) * 1992-08-07 2002-11-14 Ralph T. Kubo Hla binding peptides and their uses
US20040110283A1 (en) * 1997-02-27 2004-06-10 University Of Pittsburgh Of The Commonwealth System Of Higher Education Induction of tumor and viral immunity using antigen presenting cell co-culture products and fusion products
US20050170503A1 (en) * 1997-02-27 2005-08-04 University Of Pittsburgh In vitro induction of antigen-specific T-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens
US7282198B2 (en) * 1997-03-19 2007-10-16 The University Of Arkansas For Medical Sciences Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme
WO1999024554A2 (en) 1997-11-12 1999-05-20 University Of Pittsburgh Isolation, characterization, and identification of dendritic like cells and methods of using same
AU3305699A (en) * 1998-02-26 1999-09-15 Beckman Coulter, Inc. Prostate-specific membrane antigens and methods of making and using
AU3102599A (en) * 1998-03-20 1999-10-11 Genzyme Corporation Compositions and methods for the frozen storage of dendritic cells
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
EP1068296B1 (en) 1998-03-31 2011-08-10 Geron Corporation Compositions for eliciting an immune response to a telomerase antigen
EP1078060B1 (en) * 1998-05-11 2007-01-10 E.P. Prof. Dr. Rieber Antibodies to dendritic cells and human dendritic cell populations and uses thereof
US7351546B2 (en) * 1998-09-22 2008-04-01 Becton, Dickinson And Company Flow cytometric, whole blood dendritic cell immune function assay
US6495333B1 (en) 1998-09-22 2002-12-17 Becton Dickinson And Company Flow cytometric, whole blood dendritic cell immune function assay
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
CA2345277C (en) 1998-10-20 2011-05-24 Salvatore Albani Methods for isolation, quantification, characterization and modulation of antigen-specific t cells
US6787154B2 (en) * 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
US7807377B2 (en) 1998-10-20 2010-10-05 Salvatore Albani Method of isolating antigen-specific T cells employing artificial antigen presenting cells
GB9827103D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
CA2367692A1 (en) * 1999-03-15 2000-09-21 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
DE60044125D1 (de) 1999-04-14 2010-05-20 Novartis Vaccines & Diagnostic Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren-systeme
US7713739B1 (en) * 2000-11-17 2010-05-11 Novartis Vaccines And Diagnostics, Inc. Microparticle-based transfection and activation of dendritic cells
US7015205B1 (en) 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
KR100363587B1 (ko) * 1999-11-12 2002-12-06 이시우 대식세포와 종양세포의 융합에 의한 항종양 세포성 치료제
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
CN1454215B (zh) * 1999-11-15 2013-01-02 米勒腾尼生物技术有限公司 树突状细胞特异的抗原结合片段、组合物及其使用方法、被其识别的抗原及由其获得的细胞
AU1811801A (en) * 1999-12-03 2001-06-12 Dendreon Corporation Cryopreservation of antigen-loaded dendritic cells and their precursors in serum-free media
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US20030027246A1 (en) * 2000-03-31 2003-02-06 Artur Pedyczak Immunogenic peptides derived from prostate-specific membrane antigen (PSMA) and uses thereof
CA2408547A1 (en) * 2000-05-11 2001-11-15 Altarex Corp. Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
US20030175247A1 (en) * 2000-05-12 2003-09-18 Michael Salgaller Method to increase class I presentation of exogenous antigens by human dendritic cells
DE10041515A1 (de) * 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
CA2460014A1 (en) * 2000-09-21 2002-03-28 The Regents Of The University Of California Spas-1 cancer antigen
US20070031372A1 (en) * 2004-08-05 2007-02-08 Hadden John W Vaccine immunotherapy for immune suppressed patients
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
AU2002232560A1 (en) 2000-10-27 2002-05-06 Immuno-Rx, Inc Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) * 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
US20030082806A1 (en) * 2001-04-27 2003-05-01 Xcyte Therapies, Inc. Maturation of antigen-presenting cells using activated T cells
CA2459713C (en) 2001-09-06 2015-08-18 Northwest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
WO2003033520A2 (en) * 2001-09-24 2003-04-24 University Of Pittburgh Of The Commonwealth System Of Higher Education Anticancer vaccine and diganostic methods and reagents
US20050215472A1 (en) * 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
JP5355839B2 (ja) * 2001-10-23 2013-11-27 ピーエスエムエー デベロプメント カンパニー， エル．エル．シー． Ｐｓｍａ抗体およびタンパク質マルチマー
AU2002349543A1 (en) * 2001-12-10 2003-06-23 Kyogo Itoh Tumor antigens
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
SI1509244T1 (sl) * 2002-06-06 2011-11-30 Immunicum An Nov postopek in spojina za izdelavo celične alogenične vakcine
CN1713951B (zh) 2002-06-19 2010-05-26 西北生物治疗药物公司 切向流过滤设备和白细胞富集方法
US20040022813A1 (en) * 2002-08-05 2004-02-05 Jean-Claude Bystryn Shed antigen vaccine with dendritic cells adjuvant
JP2004196770A (ja) * 2002-10-24 2004-07-15 Effector Cell Institute Inc 樹状細胞前駆体の血中レベル上昇剤
KR100522526B1 (ko) * 2002-11-28 2005-10-19 주식회사 바이넥스 면역 치료용 수지상 세포의 제조방법
CN102600461B (zh) * 2002-12-06 2017-07-14 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤
US20040202663A1 (en) * 2003-01-28 2004-10-14 Shanghai Sunway Biotech Co., Ltd. Therapy for primary and metastatic cancers
WO2004075855A2 (en) * 2003-02-26 2004-09-10 Biomed Solutions, Llc Process for in vivo treatment of specific biological targets in bodily fluid
RU2364625C2 (ru) 2003-02-27 2009-08-20 Норсуэст Байотерапьютикс, Инк. Генерирование дендритных клеток из моноцитарных предшественников дендритных клеток с помощью gm-csf в отсутствие дополнительных цитокинов
EP1670513B1 (en) * 2003-10-06 2013-01-23 Cedars-Sinai Medical Center Cox-2 inhibitors and dendritic cells for use in the treatment of cancer.
JP5015601B2 (ja) * 2003-10-21 2012-08-29 セダーズ−シナイ メディカル センター 中枢神経系の癌を含む癌の処置のための系および方法
DE602005022728D1 (de) * 2004-08-19 2010-09-16 Univ Cardiff Präparation antigenpräsentierender menschlicher gamma delta t-zellen und verwendung in der immuntherapie
CN100591761C (zh) * 2004-08-19 2010-02-24 加的夫大学学院咨询有限公司 呈递抗原的人γδT细胞的制备和在免疫治疗中的用途
WO2006023598A2 (en) * 2004-08-19 2006-03-02 University Of Maryland, Baltimore Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
WO2007044033A2 (en) * 2004-12-07 2007-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
US8420078B2 (en) * 2005-03-10 2013-04-16 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases
CA2504279A1 (en) * 2005-04-15 2006-10-15 University Of Saskatchewan Materials and method of modulating the immune response using t helper-antigen presenting cells
EP1888105A2 (en) * 2005-05-12 2008-02-20 Introgen Therapeutics, Inc. P53 vaccines for the treatment of cancers
SG162817A1 (en) 2005-06-17 2010-07-29 Mannkind Corp Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
US8338173B2 (en) * 2005-08-11 2012-12-25 University College Cardiff Consultants Limited Preparation of antigen-presenting human γδ T cells and use in immunotherapy
KR20220113543A (ko) 2005-12-08 2022-08-12 노쓰웨스트 바이오써라퓨틱스, 인크. 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법
WO2007137300A2 (en) 2006-05-23 2007-11-29 Bellicum Pharmaceuticals, Inc. Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
CA2700436C (en) 2006-09-28 2017-04-18 John S. Yu Cancer vaccines and vaccination methods
US8097242B2 (en) * 2006-10-05 2012-01-17 The Board Of Trustees Of The University Of Arkansas Target CA125 peptides for cancer immunotherapy
JP5563472B2 (ja) 2007-11-28 2014-07-30 アイ アール エックス セーラピューティクス， インコーポレイテッド 免疫学的効果を増大させる方法
US20110189093A1 (en) * 2008-04-14 2011-08-04 Proscan Rx Pharma Prostate specific membrane antigen antibodies and antigen binding fragments
US8748170B2 (en) 2008-07-25 2014-06-10 University of Pittsburgh—of the Commonwealth System of Higher Education Polypeptides derived from cyclin B1 and uses thereof
PL2328923T3 (pl) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
EP2326350B1 (en) 2008-09-08 2013-09-04 Psma Development Company, L.L.C. Compounds for killing psma-expressing, taxane-resistant cancer cells
DK2352756T3 (da) 2008-11-24 2012-12-03 Helmholtz Zentrum Muenchen Højaffin T-cellereceptor og anvendelse af denne
EP2427485B1 (en) * 2009-05-07 2016-12-07 ImmunoCellular Therapeutics, Ltd. Cd133 epitopes
CA3017298C (en) 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
ES2667476T3 (es) 2009-12-08 2018-05-11 Irx Therapeutics, Inc. Método para invertir la supresión inmunitaria de células de Langerhans
US20110251128A1 (en) * 2010-02-26 2011-10-13 The Board Of Regents Of The University Of Texas System THYMOSIN Beta4 PEPTIDES PROMOTE TISSUE REGENERATION
US9629357B2 (en) * 2013-02-01 2017-04-25 Primegen Biotech Llc Cryopreservation of cells and tissue for clinical application
ES2662333T3 (es) 2013-02-14 2018-04-06 Immunocellular Therapeutics Ltd. Vacunas contra el cáncer y métodos de vacunación
US10320290B2 (en) * 2013-08-09 2019-06-11 Microsemi Corporation Voltage regulator with switching and low dropout modes
DK3277325T3 (da) 2015-04-03 2021-01-18 H Lee Moffitt Cancer Ct & Res Kombinationsimmunterapi for cancer
KR102873947B1 (ko) 2015-05-07 2025-10-22 베이롤 칼리지 오브 메드신 수지상 세포 면역요법
US10801041B2 (en) 2015-11-18 2020-10-13 Orbis Health Solutions, Llc T7 alpha viral vector system
US11020465B2 (en) 2016-03-04 2021-06-01 The Trustees Of Columbia University In The City Of New York Development of dual whole cell-based vaccine against pancreatic cancer
WO2017181163A2 (en) 2016-04-16 2017-10-19 Oncocyte Corporation Methods and compositions for detection and diagnosis of breast cancer
JP2021533759A (ja) * 2018-08-10 2021-12-09 ユーティレックス カンパニー リミテッド 癌抗原特異的ｃｄ８＋ｔ細胞を調製および凍結保存するための方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3753357A (en) 1970-12-14 1973-08-21 Ovitron Res Corp Method and apparatus for the preservation of cells and tissues
US4199022A (en) 1978-12-08 1980-04-22 The United States Of America As Represented By The Department Of Energy Method of freezing living cells and tissues with improved subsequent survival
US4559298A (en) 1982-11-23 1985-12-17 American National Red Cross Cryopreservation of biological materials in a non-frozen or vitreous state
US5192553A (en) * 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
US5004681B1 (en) * 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
US5162504A (en) * 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US20030072751A1 (en) * 1990-03-14 2003-04-17 Heribert Bohlen Idiotypic vaccination against b cell lymphoma
US5227471A (en) * 1992-01-30 1993-07-13 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma
AU4678993A (en) * 1992-07-16 1994-02-14 Board Of Trustees Of The Leland Stanford Junior University Methods for using dendritic cells to activate t cells
EP0692973A1 (en) * 1993-03-15 1996-01-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Peptide coated dendritic cells as immunogens
PT765386E (pt) * 1994-06-14 2015-02-06 Univ Leland Stanford Junior Processos para a activação in vivo de células t, através de células dendríticas pulsadas com antigénio

Also Published As

Publication number Publication date
WO1997004802A1 (en) 1997-02-13
US20130017600A1 (en) 2013-01-17
DE841940T1 (de) 2001-08-23
CA2228176C (en) 2015-05-26
JP2001520633A (ja) 2001-10-30
AU6714696A (en) 1997-02-26
AU723607B2 (en) 2000-08-31
US5788963A (en) 1998-08-04
MX9800821A (es) 1998-10-31
EP0841940A4 (en) 2005-01-05
JP4267692B2 (ja) 2009-05-27
EP2377548A3 (en) 2012-10-10
CA2228176A1 (en) 1997-02-13
EP2377548A2 (en) 2011-10-19
EP0841940A1 (en) 1998-05-20
NZ315441A (en) 1999-06-29

Similar Documents

Publication Publication Date Title
IL123079A0 (en) Compositions and methods for producing a cancer growth inhibiting response
HUP9802535A3 (en) Seed shattering
GB2297690B (en) Artificial flower
GB9510927D0 (en) Plant and seed oil modification
EP0723750A3 (de) Uhren-Armband und Verfahren zu dessen Herstellung
IL116836A0 (en) Plant growth stimulating composition
GB9510563D0 (en) Well inhibition
PL323389A1 (en) Caprolaktam producing method
GB9620607D0 (en) Furopyridine derivatives
GB9602462D0 (en) Seed planter
GB9513382D0 (en) Planters
CA75600S (en) Planter
KR0110192Y1 (en) Artificial flower
HU791U (en) Plough
PL57347Y1 (en) Power-lift-mounted deep-tillage plough
GB9509493D0 (en) Multi-share plough
GB9515900D0 (en) Flower mesh
CA75476S (en) Landscaping block
GB9515038D0 (en) Plant growth unit
ZA966530B (en) A pharmaceutical composition for inhibiting the growth of cancers
KR0111967Y1 (en) Seeder
HU9600304D0 (en) Procesfor producing fluoro-cyclopropane derivatives
GB9514043D0 (en) Seed run
AU127546S (en) Ornament
GB9502367D0 (en) Flower barrow vending machien

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
EXP Patent expired